Showing 7551-7560 of 9822 results for "".
- Review Examines Potential of AI Tools for Physician Burnouthttps://practicaldermatology.com/news/streamlining-charting-ai-tools/2470864/Patient documentation tools powered by AI have the potential to alleviate burnout among dermatologists by streamlining administrative tasks, according to a recent review published in the Journal of Drugs in Dermatology. "The prevalence of burnout among United States (US) dermatolo
- Higher WWI Linked to Increased Mortality Rates in Psoriasis Patientshttps://practicaldermatology.com/news/higher-wwi-linked-increased-mortality-rates-psoriasis-patients/2470869/New research indicates a strong positive correlation between weight-adjusted waist index (WWI) and all-cause mortality in psoriasis patients. Researchers at Wenzhou Medical University in China published “Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHA
- Hair Care Market to Reach $20B by 2029: Reporthttps://practicaldermatology.com/news/hair-care-market-reach-20b-2029-report/2470831/The U.S. hair care market is projected to reach $20 billion by 2029, according to a report released by ResearchAndMarkets.com. The report noted that hair care remains resilient despite economic fluctuations due to consumer demand for premium and sustainable products and cited the rising p
- Analysis: No Risk Differences in MACE and VTE Among Biologics for Psoriatic Diseasehttps://practicaldermatology.com/news/analysis-no-risk-differences-mace-and-vte-among-biologics-psoriatic-disease/2470809/A recent cohort analysis revealed no significant differences in the risks of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) among biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) treated with different classes of biologics. Researchers
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://practicaldermatology.com/news/report-regenerative-aesthetics-exosome-market-poised-355-cagr-through-2031/2470805/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin rejuvenation, hair restoration, scar redu
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- Review: Potential and Challenges for Exosomes in Cosmetic Dermatologyhttps://practicaldermatology.com/news/review-potential-and-challenges-exosomes-cosmetic-dermatology/2470764/Exosomes show promise for enhancing skin and hair health, but key challenges must be addressed before they can be widely adopted in cosmetic dermatology, according to a new literature review in the Journal of Drugs in Dermatology. Exosomes, extracellular vesicles responsible for cellular c
- Key Thickness Benchmark Identified for Thin Melanoma Death Riskhttps://practicaldermatology.com/news/key-thickness-benchmark-identified-thin-melanoma-death-risk/2470668/Melanomas with Breslow thickness between 0.8 and 1.0 mm are associated with nearly triple the risk of melanoma-related death compared to thinner melanomas, a new study of Australian registry data reports. "Most patients who present with primary cutaneous melanomas have thin tumors (≤ 1.0 m